Answers are grounded in this paper and cite their sources.
Flavones are a subclass of flavonoids, the plant-derived polyphenolic compounds that are biologically constructed in terms of chemical structure and are constructed around a 2-phenylchromen-4-one nucleus which can be considered to be a class of evolutionarily privileged natural products designed to fit into various biological systems. The conventional "one drug, one target" approach to the treatment of the various complex multifactorial diseases that afflict mankind, like cancer, diabetes and neurodegenerative diseases, has been increasingly found wanting and attention has re-focused on multi-target therapeutics, i.e., polypharmacology, which seeks to effect simultaneous multi-point modulations of the various abnormalities associated with these diseases via the use of a single chemical entity. The current review gives a comprehensive analysis of the new developments that are reported in the use of flavone derivatives as multi-target therapeutic agents. This includes both the chemical and biological rationale for their suitability for use as polypharmacological agents. There is a detailed assessment of the important approaches that are possible, including inspiration from natural products, synthetic modifications of these compounds (thionation, halogenation, carbamoylation) to overcome pharmacokinetic limitations, and the rational design of novel hybrid molecules incorporating two or more pharmacophores to give synergistic results. The therapeutic effects of these new derivatives are considered in some detail covering their effects in Alzheimer's Disease, Parkinsonism, cancers and diabetes mellitus where they would seem to modulate pathological processes in inflammation, oxidative stress, cell signalling and metabolism at one and the same time. Finally, the review deals with some of the crucial translational aspects such as bioavailability and possible toxicity and gives a critical account of future possibilities such as the introduction of new advanced delivery systems and the harvesting of artificial intelligence in the considerations of drug design.
No takes yet. Share an insight, caveat, or question.
Choudhury et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: